{"schema_version":"secwatch.filing_event.v1","accession":"0001906324-24-000030","form_type":"8-K","ticker":"QDEL","cik":"0001906324","company_name":"QuidelOrtho Corp","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.174459+00:00","generated_at":"2026-06-02T13:49:58.421416+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"QuidelOrtho Q1 revenue $711M, GAAP loss $25.50/share; suspends 2024 guidance after new CEO","bullets":["Total revenue $711M, down 16% YoY; ex-COVID revenue grew 5% as reported (6% constant currency).","GAAP diluted loss per share $25.50 from $1.74B goodwill impairment; adjusted EPS $0.44 vs $1.80.","Appointed Brian J. Blaser CEO effective May 6; suspended 2024 financial guidance.","Cost reduction headcount cuts expected to deliver ~$100M annualized savings.","Secured credit agreement amendment for additional flexibility through 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001906324-24-000030","json":"https://secwatch.observer/filing/0001906324-24-000030.json","markdown":"https://secwatch.observer/filing/0001906324-24-000030.md","text":"https://secwatch.observer/filing/0001906324-24-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1906324/000190632424000030/0001906324-24-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1906324/000190632424000030/qdel-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T13:49:58.421416+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1812a69e9a921de8f8eb4e12c4ffc5fad792f686","claim":"QuidelOrtho Corp reported first quarter ended March 31, 2024 results: revenue $711 million, EPS GAAP diluted loss per share for the first quarter of 2024 was $25.50.","evidence_excerpt":"suspends 2024 financial guidance while it assesses business under new President and Chief Executive Officer - First Quarter 2024 Results and Recent Highlights • Revenue was $711 million, as reported: ◦ Non-respiratory revenue was flat at $574 million compared to the prior year period, as reported and in constant currency ▪ Excluding the one-time third-party","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1906324/000190632424000030/0001906324-24-000030-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$711 million"},{"label":"EPS","value":"GAAP diluted loss per share for the first quarter of 2024 was $25.50"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}